Inotek Pharmaceuticals Announces Participation in Ophthalmology Panel at 18th Annual BIO CEO & Investor Conference on February 8th

LEXINGTON, Mass.--()--Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will participate in an ophthalmology panel at the 18th Annual BIO CEO & Investor Conference. The panel will take place in New York City at the Waldorf Astoria Hotel on Monday, February 8, 2016 at 9:30 am EST.

The panel, titled “Advances in Ophthalmology: Therapies for Saving Sight,” will be moderated by Tony Gibney, Managing Director at Leerink Partners.

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek's laboratories and designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit www.inotekpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These forward-looking statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Inotek:
Claudine Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com
or
Media:
Sarah D’Souza, 781-424-2548
Director of Communications
sdsouza@inotekpharma.com

Release Summary

Inotek announced that David P. Southwell, President and Chief Executive Officer, will participate in an ophthalmology panel at the 18th Annual BIO CEO & Investor Conference.

Contacts

Inotek:
Claudine Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com
or
Media:
Sarah D’Souza, 781-424-2548
Director of Communications
sdsouza@inotekpharma.com